Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry

Spronsen, Dick Johan van; Janssen‐Heijnen, M.L.G.; Lemmens, Valery; Peters, W.; Coebergh, Jan Willem

doi:10.1016/j.ejca.2005.01.010

Cited by 77 publications

(48 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…57 Besides, in the presence of comorbidity, the percentage of patients receiving chemotherapy declined, especially among elderly patients. 58 This is supported by the significantly higher proportion of elderly patients in our study compared to clinical trials, with a mean age of 66 years in our study versus 61 years in the study of Cunningham. 20 A considerable number of the elderly patients in our study did not receive any treatment and consequently they had a low survival rate.…”

Section: Discussionsupporting

confidence: 75%

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 75%

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The negative effect of older age on long-term survival generally reflects the reduced ability of older patients to tolerate intensive salvage therapy, the age-related propensity for late doxorubicin-induced cardiomyopathy, but also increased mortality from co-morbidity. 31,[33][34][35][36][37] The prognosis of B-cell NHL patients has improved in recent decades due to the introduction of more effective drugs for newly diagnosed and relapsed patients (e.g. rituximab), 38,39 to which the large scale HOVON trials may have contributed in the Netherlands.…”

Section: Discussionmentioning

confidence: 99%

Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands

et al. 2013

View full text Add to dashboard Cite

© F e r r a t a S t o r t i F o u n d a t i o nstage, 16 were obtained routinely from the medical records about 9 months after diagnosis.In addition to passive follow-up via the hospitals, date of death was also retrieved from the Municipal Personal Records Database. Follow-up of vital status was complete until January, 1 st , 2010. For the present study, all patients with mature B-cell NHL newly diagnosed in the period [1989][1990][1991][1992][1993][1994][1995][1996][1997][1998][1999][2000][2001][2002][2003][2004][2005][2006][2007][2008] in the Netherlands were included (n=54,015). Patients with plasma cell neoplasms were excluded. NHL entities were defined according to the World Health Organization classification, 4 th edition. 18 The exact codes used for each entity are described in a previous publication.2 Sufficient patients were available to report the entity-specific conditional relative survival for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).We also used two major diagnostic subgroups, based on a combination of entities of more or less similar clinical behavior and comparable response to therapies: indolent and aggressive B-cell neoplasms. The entities included in each subgroup are shown in Table 1. Unspecified cases were excluded from these analyses.Patients younger than 15 years and older than 89 years were excluded from the analysis, as were cases diagnosed at autopsy. Patients were divided into four age groups (15-44, 45-59, 60-74, and 75-89 years old). Patients aged 15-29 and 30-44 years were merged, because of the small numbers. Statistical analysesRelative survival is an approximation of disease-specific survival. It is calculated as the absolute survival among cancer patients divided by the expected survival of a comparable group from the general population (same period, age, and gender). Expected survival was calculated from population life tables from the Netherlands, according to the Ederer II method. 19 Period analysis 20,21 was used to provide up-to-date survival estimates; all observations included in the analysis are left-truncated at the beginning of the period of interest, in addition to being right-censored at its end. Furthermore, to enable the estimation of even more up-to-date survival, hybrid analysis was used. 22Five-year relative survival rates were computed for every additional year of survival up to 15 years after diagnosis, conditional on being alive at the beginning of that year (conditional 5-year relative survival, CRS), unadjusted for other variables. Conditional survival was computed according to disease entity, grade, gender, 15-year age group, and stage of disease. For the analysis according to period of diagnosis (1995-2000 versus 2003-2008) conditional 3-year relative survival rates were computed, since follow-up time for patients diagnosed in 2003-2008 was limited. When the CRS pe...

show abstract

“…In a population-based study, van Spronsen et al reported that among eHL, 56% had a serious comorbid condition versus 13% in younger patients (P Ͻ .0001). 19 Levis et al reported results of eHL patients who received lowerintensity chemotherapy 20 ; multivariate analysis found that the . The numbers of patients with 0, 1, or 2 factors at diagnosis were 48, 38, and 9, respectively; increasing number of risk factors portended an increasingly poor survival.…”

Section: Functional Statusmentioning

confidence: 99%

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Evens

Helenowski

Ramsdale

et al. 2012

Blood

144

122

View full text Add to dashboard Cite

We investigated a recent (January 1999 to December 2009) cohort of 95 elderly Hodgkin lymphoma subjects. At diagnosis, median age was 67 years (range, 60-89 years), whereas 61% had significant comorbidity, 26% were unfit, 17% had a geriatric syndrome, and 13% had loss of activities of daily living. Overall response rate to therapy was 85%, whereas incidence of bleomycin lung toxicity was 32% (with associated mortality rate, 25%). With 66-month median follow-up, 2-year and 5-year overall survival were 73% and 58%, respectively (advanced-stage, 63% and 46%, respectively). Most International Prognostic Score factors were not prognostic on univariate analyses, whereas Cox multivariate regression identified 2 risk factors associated with inferior overall survival: (1) age more than 70 years (2.24; 95% CI, 1.16-4.33, P ‫؍‬ .02) and (2) loss of activities of daily living (2.71; 95% CI, 1.07-6.84, P ‫؍‬ .04). Furthermore, a novel survival model based on number of these risk factors (0, 1, or 2) showed differential 2-year OS of 83%, 70%, and 13%, respectively (P < .0001) and 5-year OS of 73%, 51%, and 0%, respectively (P < .0001). (Blood. 2012; 119(3):692-695)

show abstract

Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry

Cited by 77 publications

References 31 publications

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010

Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Contact Info

Product

Resources

About